MINKSneuro s.r.o.

The research team at MINKSneuro s.r.o. is conducting a study to assess a novel antibody therapy, nipocalimab, for an autoimmune neuromuscular disorder, Generalized Myasthenia Gravis. It aims to determine whether the treatment can improve patients’ daily activities and reduce disease‑related antibodies.

• Evaluation of treatment efficacy using patient‑reported outcome scales
• Comparison of subcutaneous and intravenous delivery routes
• Monitoring of immunoglobulin G levels as a pharmacodynamic marker

Successful results could offer a new therapeutic option for individuals living with this chronic condition and inform dosing strategies for future development.

A safety and tolerability study is underway to explore a new compound for managing chronic nerve pain characterized by heightened sensitivity to touch. The investigational drug, PN6047 HCl, is being evaluated in participants with mechanical allodynia stemming from peripheral neuropathic pain.

• Assessment of adverse events and overall safety profile
• Measurement of pain intensity reduction over time
• Investigation of the drug’s mechanism in neuropathic pathways

Findings may expand treatment options for patients whose pain is resistant to existing therapies and guide future analgesic research.